Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2022 | The important role of the multidisciplinary team in CAR-T therapy

Mohamad Mohty • 25 Aug 2022
IMS 2022
Multiple Myeloma CAR-T Ciltacabtagene autoleucel Idecabtagene vicleucel

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the multidisciplinary roles involved in delivering CAR-T therapy. Prof. Mohty explains the input needed from multiple individuals, such as practitioners, apheresis teams, neurologists, ICU teams, and infectious diseases teams. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

More from Mohamad Mohty

Advances in GvHD management presented at ASH 2025 5:07
Advances in GvHD management presented at ASH 2025
Mohamad Mohty • 5 Dec 2025
Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
Mohamad Mohty et al. • 15 Jul 2022
Optimizing conditioning regimens for SCT in AML and MDS 3:38
Optimizing conditioning regimens for SCT in AML and MDS
Mohamad Mohty • 31 Mar 2025
Optimizing anti-CD38 monoclonal antibody-based quadruplet therapies in newly diagnosed myeloma 4:28
Optimizing anti-CD38 monoclonal antibody-based quadruplet therapies in newly diagnosed myeloma
Mohamad Mohty • 31 Mar 2025

Related Videos

The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma 4:45
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
Ola Landgren • 6 Dec 2025
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry 1:29
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry
Karthik Ramasamy • 7 Dec 2025
The hottest myeloma abstracts from ASH 2025: in vivo CAR-T and MajesTEC-3 2:33
The hottest myeloma abstracts from ASH 2025: in vivo CAR-T and MajesTEC-3
Faith Davies • 7 Dec 2025
Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL 2:30
Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL
James Berenson • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals